Exhibit 10.10
                          FOURTH AMENDMENT AND CONSENT
                         TO LOAN AND SECURITY AGREEMENT


     FOURTH AMENDMENT AND CONSENT,  dated as of May 5, 1998 (this  "Amendment"),
to the Loan and  Security  Agreement  referred  to  below by and  among  GENERAL
ELECTRIC  CAPITAL   CORPORATION,   a  New  York  corporation   ("Lender"),   PAR
PHARMACEUTICAL,  INC.,  a New Jersey  corporation  ("Borrower"),  PHARMACEUTICAL
RESOURCES,  INC., a New Jersey corporation ("Parent"),  NUTRICEUTICAL RESOURCES,
INC., a New York corporation ("NRI"), and PARCARE,  LTD., a New York corporation
("ParCare").   Parent,   NRI  and  ParCare  are   hereinafter   referred  to  as
"Guarantors".

                               W I T N E S S E T H

     WHEREAS,  Lender,  Borrower and Guarantors are parties to that certain Loan
and Security Agreement, dated as of December 15, 1996 (as amended,  supplemented
or otherwise modified prior to the date hereof, the "Loan Agreement");

     WHEREAS,  Lender,  Borrower  and  Guarantors  have agreed to amend the Loan
Agreement in the manner,  and on the terms and conditions,  provided for herein;
and

     WHEREAS,  Lender has agreed to consent to certain  actions by Borrower  and
Parent under the Loan Agreement in the manner,  and on the terms and conditions,
provided for herein.

     NOW  THEREFORE,  in  consideration  of the  premises and for other good and
valuable  consideration,  the  receipt,  adequacy and  sufficiency  of which are
hereby acknowledged, the parties to this Amendment hereby agree as follows:

     1.  Definitions.  Capitalized terms not otherwise defined herein shall have
the meanings ascribed to them in the Loan Agreement.

     2.  Amendment  to Section 5(d) of the Loan  Agreement.  Section 5(d) of the
Loan  Agreement  is  hereby  amended  and  restated  in its  entirety  as of the
Amendment Effective Date (as hereinafter defined) to read as follows:

          "(d) enter into any lending, borrowing or other commercial transaction
          with any of its employees,  directors,  Affiliates or any other Credit
          Party   (including   upstreaming   and   downstreaming   of  cash  and
          intercompany  advances,  and  payments by a Credit  Party on behalf of
          another  Credit  Party which are not  otherwise  permitted  hereunder)
          other than (i) loans to employees  in the ordinary  course of business
          in an aggregate  outstanding amount not exceeding $50,000,  (ii) those
          transactions  contemplated  under the Merck Equity Documents and (iii)
          indebtedness  consisting  of  intercompany  loans made by  Borrower to
          Parent  provided  that  (A)  Borrower  and  Parent  shall  record  all
          intercompany  transactions  on their  books  and  records  in a manner
          satisfactory to Lender, (B) no Default or Event of Default would occur
          and  be   continuing   after  giving   effect  to  any  such  proposed



          intercompany   loan,  and  (C)  the  aggregate   amount  of  all  such
          intercompany  loans  made by  Borrower  to  Parent  shall  not  exceed
          (together with any dividends under Section 5(l)(iv) below)  $1,200,000
          in any Fiscal Year;"

     3.  Amendment  to Section 5(i) of the Loan  Agreement.  Section 5(i) of the
Loan  Agreement  is  hereby  amended  and  restated  in its  entirety  as of the
Amendment Effective Date to read as follows:

          "(i) sell, transfer,  convey,  assign or otherwise dispose
          of  any  of  its  assets  or  properties,   including  its
          Accounts, or issue any shares of its Stock; provided, that
          the foregoing shall not prohibit (i) the sale of Inventory
          or obsolete or unnecessary Equipment or real estate in the
          ordinary  course of its business,  (ii) the sale by Parent
          of  its  Common  Stock  at  Fair  Market  Value  for  cash
          consideration  so long as the proceeds thereof are applied
          to prepayment  of Revolving  Credit  Advances  pursuant to
          Section 1.2(c),  (iii) issuance by Parent of shares of its
          Common Stock upon exercise of the Warrants,  (iv) issuance
          by Parent to its  employees  of  options to  purchase  its
          Common  Stock  pursuant  to the  Stock  Option  Plans  and
          issuance of Common  Stock upon  exercise of such  options,
          (v)  issuance  by  Parent  to  members  of  its  Board  of
          Directors of options to purchase its Common Stock pursuant
          to the 1997  Directors  Stock Option Plan,  adopted by the
          Board of  Directors  of Parent on October  28,  1997,  and
          issuance of Common  Stock upon  exercise of such  options,
          and (vi)  issuance by Parent to employees of Genpharm Inc.
          of  options  to  purchase  up to an  aggregate  of 120,000
          shares of its Common Stock pursuant to a stock option plan
          to be  adopted  by the Board of  Directors  of Parent  and
          issuance of Common Stock upon exercise of such options."

     4.  Amendment to Schedule A to the Loan  Agreement.  Schedule A to the Loan
Agreement is hereby amended as of the Amendment Effective Date as follows:

     (a) The  definition  of "Merck  Equity  Documents"  is hereby  amended  and
restated in its entirety to read as follows:

                    '"Merck    Equity    Documents"    shall    mean,
           collectively, the Merck Stock Purchase Agreement, the Clal
           Letter Agreement, the Merck Services Agreements, the Merck
           Distribution  Agreement,  the Merck Option  Agreements and
           the Merck Registration Rights Agreement."

     (b) The  definition of "Merck Stock  Purchase  Agreement" is hereby amended
and restated in its entirety to read as follows:

                    '"Merck Stock Purchase Agreement" shall mean that
           certain Stock  Purchase  Agreement,  dated March 25, 1998,
           between Parent and Lipha Americas, Inc."


                                       -2-



     (c) The definition of "Overadvance Limit" is hereby amended and restated in
its entirety to read as follows:

                     '"Overadvance  Limit"  shall mean for each period
            the amount set forth below for such period:

                     Period                      Overadvance Limit
                     ------                      -----------------

            2/17/98 through 4/1/98                  $2,000,000
            4/1/98 through 6/19/98                  $2,500,000
            6/20/98 and thereafter                  $        0"

     (d)  The  following  new  definitions  shall  be  inserted  in  the  proper
alphabetical order:

                '"Clal Letter  Agreement" shall mean that certain
          letter  agreement,  dated March 25,  1998,  among  Parent,
          Merck and Clal Pharmaceutical Industries Ltd.

                 "Merck  Distribution  Agreement"  shall mean that
          certain  Agreement,  dated as of March 25,  1998,  between
          Parent and Genpharm Inc."

                 '"Merck    Option    Agreements"    shall   mean,
          collectively,  that certain (i) Stock Option  Agreement to
          be entered into between  Parent and Merck,  and (ii) Stock
          Option  Agreement to be entered  into  between  Parent and
          Genpharm  Inc.,  each in the form  attached  to the  Merck
          Stock Purchase Agreement."

                 '"Merck Registration Rights Agreement" shall mean that certain
          Registration Rights Agreement to be entered into among Parent, Merck,
          Genpharm Inc. and Lipha Americas, Inc. in the form attached to the
          Merck Stock Purchase Agreement."

                  '"Merck   Services    Agreements"   shall   mean,
          collectively,  that certain (i)  Services  Agreement to be
          entered  into between  Parent and Merck and (ii)  Services
          Agreement to be entered into between  Parent and Genpharm,
          each substantially in the form attached to the Merck Stock
          Purchase Agreement."

     5.  Consent.  (a) Lender  hereby  consents to the amendment by Borrower and
Parent of that certain Amended and Restated Distribution Agreement,  dated as of
July 28, 1997, as amended, supplemented or otherwise modified from time to time,
among SANO Corporation ("SANO"),  Borrower and Parent, in the manner, and on the
terms and conditions set forth in, that certain  letter  agreement,  dated March
31, 1998, among SANO, Borrower and Parent, a copy of which is attached hereto as
Exhibit A.

     (b) Lender  hereby  acknowledges  that the form and  substance of the Merck
Equity Documents are satisfactory to Lender and further consents, under all

                                       -3-


provisions  of the Loan  Agreement,  to the  execution  and delivery  thereof by
Parent and the consummation of the transactions contemplated therein;  provided,
that all proceeds  received by Parent under the Merck Equity  Documents shall be
immediately  contributed to the capital of Borrower and  immediately  applied by
Borrower to prepayment of Revolving  Credit Advances  pursuant to Section 1.2(c)
of the Loan Agreement.  To the extent any proceeds remain after such prepayment,
Borrower  shall  immediately   invest  such  proceeds  solely  in  a  "Permitted
Investment" until such time as any of the Credit Parties shall use such proceeds
for such uses as shall not be  prohibited  by the Loan  Agreement.  The  parties
agree that such an investment  and such uses shall not constitute a violation of
the Loan Agreement. For purposes of this Amendment, "Permitted Investment" shall
mean (i) marketable direct obligations  issued or unconditionally  guaranteed by
the United  States of America or any agency  thereof  maturing  no more than one
year from the date of creation  thereof,  (ii) commercial paper maturing no more
than one year from the date of creation thereof and currently having the highest
rating obtainable from either Standard & Poor's Corporation or Moody's Investors
Service,  Inc.,  (iii)  certificates of deposit,  maturing no more than one year
from the date of creation thereof, issued by commercial banks incorporated under
the laws of the United States of America, each having combined capital,  surplus
and undivided  profits of not less than $300,000,000 and having a senior secured
rating of "A" or better by a  nationally  recognize  rating  Agency (an "A Rated
Bank"),  and (iv) time deposits,  maturing no more than 30 days from the date of
creation thereof, with A Rated Banks.  Notwithstanding  anything to the contrary
contained  in this  Section  4(b),  (A) Lender  hereby  reserves its right under
Section 3.25 of the Loan  Agreement  to perfect its Lien in the  above-mentioned
proceeds and Permitted Investments and (B) Parent shall not amend, supplement or
otherwise  modify the Merck Equity  Documents after the date hereof,  except for
those amendments, supplements or modifications (1) of the Merck Equity Documents
which do not materially  and adversely  affect Lender and the Credit Parties and
(2) of the Merck Distribution Agreement which are made in the ordinary course of
business. Parent shall promptly deliver to Lender all documents relating to such
amendments, supplements or modifications.

     (c) Lender  hereby  consents  to the  proposed  amendment  to Article IV of
Parent's  Certificate  of  Incorporation  to increase  the number of  authorized
shares of Common Stock from 60,000,000 to 90,000,000  shares,  and the amendment
to Section 6 of Article III of Parent's  By-Laws,  each of which shall be in the
respective form set forth on Exhibit B hereto.

     (d) Lender hereby consents to the cancellation by Parent of indebtedness in
the original principal amount of $343,057.38 owing to it by Kenneth I. Sawyer in
accordance  with  the  terms  of the  proposed  form  of  Amended  and  Restated
Promissory  Note,  to be executed  by Kenneth I. Sawyer in favor of Parent,  the
form of which is attached hereto as Exhibit C.

     6.  Representations  and  Warranties.  To induce  Lender to enter into this
Amendment, each Credit Party hereby represents and warrants that:

               A. The execution,  delivery and  performance by each Credit Party
          of this Amendment:  (i) are within their respective  corporate powers;
          (ii)  have  been  duly  authorized  by  all  necessary  corporate  and
          shareholder  action;  and  (iii)  are  not  in  contravention  of  any

                                      -4-


          provision   of  their   respective   certificates   or   articles   of
          incorporation or by-laws or other organizational documents.

               B. This  Amendment  has been duly executed and delivered by or on
          behalf of each Credit Party.

               C.  This  Amendment   constitutes  a  legal,  valid  and  binding
          obligation of each Credit Party enforceable  against each Credit Party
          in accordance with its terms,  except as enforceability may be limited
          by applicable bankruptcy,  insolvency,  reorganization,  moratorium or
          similar laws  affecting  creditors'  rights  generally  and by general
          equitable  principles (whether enforcement is sought by proceedings in
          equity or at law).

               D. No Default  has  occurred  and is  continuing  both before and
          after giving effect to this Amendment.

               E. No  action,  claim or  proceeding  is now  pending  or, to the
          knowledge of each Credit Party,  threatened  against any Credit Party,
          at law, in equity or otherwise,  before any court, board,  commission,
          agency or instrumentality  of any federal,  state, or local government
          or of any agency or subdivision  thereof,  or before any arbitrator or
          panel of  arbitrators,  which  challenges  any Credit  Party's  right,
          power,  or competence  to enter into this  Amendment or, to the extent
          applicable,  perform any of its obligations under this Amendment,  the
          Loan  Agreement  or  any  other  Loan  Document,  or the  validity  or
          enforceability of this Amendment, the Loan Agreement or any other Loan
          Document or any action taken under this Amendment,  the Loan Agreement
          or any other Loan Document.

     7. No Other Consents/Waivers. Except as otherwise provided herein, the Loan
Agreement  shall be unmodified and shall continue to be in full force and effect
in accordance with its terms,  and, except as expressly  provided  herein,  this
Amendment  shall  not be  deemed a waiver  of,  or  consent  under,  any term or
condition of any Loan Document and shall not be deemed to prejudice any right or
rights  which  Lender  may  now  have  or may  have in the  future  under  or in
connection  with any  Loan  Document  or any of the  instruments  or  agreements
referred  to  therein,  as the  same may be  amended  from  time to  time.  This
Amendment shall constitute  notice to Lender,  pursuant to Section 3.8(a)(i) and
(iii) of the Loan  Agreement,  of the  transactions  contemplated  by the  Merck
Equity Documents.

     8.  Outstanding  Indebtedness;  Waiver of Claims.  Each Credit Party hereby
acknowledges  and agrees  that as of April 29,  1998 the  aggregate  outstanding
principal  amount of the Revolving Credit Loan is  $10,374,430.37  and that such
principal  amount is payable  pursuant to the Loan  Agreement  without  defense,
offset,  withholding,  counterclaim  or deduction of any kind. Each Credit Party
hereby waives,  releases,  remises and forever  discharges Lender and each other
Indemnified  Person from any and all Claims of any kind or  character,  known or
unknown,  which each  Credit  Party ever had,  now has or might  hereafter  have
against Lender which relates,  directly or indirectly,  to any acts or omissions
of Lender or any other Indemnified Person on or prior to the date hereof.


                                       -5-


     9. Expenses. Borrower hereby reconfirms its obligations pursuant to Section
10.2 of the  Loan  Agreement  to pay and  reimburse  Lender  for all  reasonable
out-of-pocket  expenses  (including,  without  limitation,  reasonable  fees  of
counsel) incurred in connection with the negotiation, preparation, execution and
delivery of this Amendment and all other documents and instruments  delivered in
connection herewith.

     10.  Effectiveness.   This  Amendment  shall  become  effective  only  upon
satisfaction  in full in the  judgment  of the  Lender of each of the  following
conditions on or prior to May 8, 1998:

               A. Amendment.  Lender shall have received four original copies of
          this  Amendment  duly executed and delivered by Lender and each Credit
          Party.

               B.  Representations  and  Warranties.   All  representations  and
          warranties of or on behalf of each Credit Party in this  Amendment and
          all the other Loan Documents shall be true and correct in all respects
          with the same effect as though such representations and warranties had
          been made on and as of the date  hereof and on and as of the date that
          the other conditions precedent in this Section 10 have been satisfied,
          except  to  the  extent  that  any  such  representation  or  warranty
          expressly relates to an earlier date.

     11.  GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY, AND INTERPRETED IN
ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

     12.  Counterparts.  This Amendment may be executed by the parties hereto on
any number of separate  counterparts and all of said counterparts taken together
shall be deemed to constitute one and the same instrument.

                            (SIGNATURE PAGES FOLLOW)

                                       -6-



     IN WITNESS  WHEREOF,  the parties  hereto have caused this  Amendment to be
duly executed and delivered as of the day and year first above written.

                                     Borrower:

                                     PAR PHARMACEUTICAL, INC.


                                     By:  /s/ Dennis O'Connor
                                        --------------------------------
                                     Name: Dennis O'Connor
                                     Title:  Vice President & Chief Financial
                                             Officer


                                     Lender:

                                     GENERAL ELECTRIC CAPITAL
                                     CORPORATION


                                     By:  /s/ Martin S. Greenberg
                                        --------------------------------
                                     Name:  Martin S. Greenberg
                                     Its:  Duly Authorized Signatory


                                     Parent:

                                     PHARMACEUTICAL RESOURCES,
                                      INC.


                                     By:  /s/ Dennis O'Connor
                                        --------------------------------
                                     Name: Dennis O'Connor
                                     Title:  Vice President & Chief Financial
                                             Officer





                       (SIGNATURES CONTINUED ON NEXT PAGE)

                                       -7-




                                     Subsidiary Guarantors:

                                     NUTRICEUTICAL RESOURCES, INC.


                                     By:  /s/ Dennis O'Connor
                                        --------------------------------
                                        Name: Dennis O'Connor
                                        Title:  Vice President & Chief Financial
                                                  Officer


                                     PARCARE, LTD.


                                     By:  /s/ Dennis O'Connor
                                        --------------------------------
                                        Name: Dennis O'Connor
                                        Title:  Vice President & Chief Financial
                                                    Officer



                                       -8-